Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 Compared With Glimepiride in the Treatment of Subjects With Type 2 Diabetes Mellitus Not Optimally Controlled on Metformin Monotherapy

Next Previous
Trial Profile

A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 Compared With Glimepiride in the Treatment of Subjects With Type 2 Diabetes Mellitus Not Optimally Controlled on Metformin Monotherapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Canagliflozin (Primary) ; Glimepiride
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms CANTATA-SU
  • Sponsors Janssen Research & Development; Johnson & Johnson

Most Recent Events

  • 08 Jul 2022 Results of post-hoc analysis of five studies (NCT01081834, NCT01106677, NCT00968812, NCT01032629 & NCT01989754) assessing efficacy of canagliflozin in diabetes subgroups stratified by data-driven clustering or a supervised machine learning method, published in the Diabetologia.
  • 15 Sep 2017 Results of a post-hoc analysis assessing the effects of Canagliflozin versus Glimepiride on select adipokines (n=200), inflammatory markers, and chemokines presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
  • 01 Dec 2016 Pooled analysis of 7 studies including this one and results of substudy of the CANVAS trial (n=432) were published in the Diabetes Therapy.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top